

# Bhaskar Dasgupta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5040232/publications.pdf>

Version: 2024-02-01

133  
papers

9,023  
citations

71097

41  
h-index

43886

91  
g-index

138  
all docs

138  
docs citations

138  
times ranked

5086  
citing authors

#	ARTICLE	IF	CITATIONS
1	Trial of Tocilizumab in Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2017, 377, 317-328.	27.0	974
2	EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 636-643.	0.9	753
3	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 19-30.	0.9	667
4	2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 484-492.	0.9	451
5	BSR and BHPR guidelines for the management of giant cell arteritis. <i>Rheumatology</i> , 2010, 49, 1594-1597.	1.9	410
6	Polymyalgia Rheumatica and Giant Cell Arteritis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2442.	7.4	346
7	The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. <i>Health Technology Assessment</i> , 2016, 20, 1-238.	2.8	313
8	2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Arthritis and Rheumatism</i> , 2012, 64, 943-954.	6.7	273
9	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 952-957.	0.9	258
10	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1799-1807.	0.9	220
11	BSR and BHPR guidelines for the management of polymyalgia rheumatica. <i>Rheumatology</i> , 2010, 49, 186-190.	1.9	213
12	Tocilizumab (Actemra). <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1972-1988.	3.3	193
13	Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. <i>Nature Reviews Rheumatology</i> , 2017, 13, 578-592.	8.0	161
14	Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group. <i>RMD Open</i> , 2018, 4, e000598.	3.8	155
15	The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 129-135.	0.9	149
16	2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2569-2580.	5.6	146
17	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 305-317.	13.7	145
18	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	6.2	144

#	ARTICLE	IF	CITATIONS
19	The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. <i>Rheumatology</i> , 2017, 56, kew273.	1.9	138
20	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, e1-e23.	1.9	128
21	Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1607-1615.	0.9	125
22	Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. <i>Arthritis and Rheumatism</i> , 2007, 57, 803-809.	6.7	122
23	Design of the Tocilizumab in Giant Cell Arteritis Trial. <i>International Journal of Rheumatology</i> , 2013, 2013, 1-10.	1.6	96
24	Health-related utility values of patients with primary Sjögren's syndrome and its predictors. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1362-1368.	0.9	87
25	Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 447-453.	0.9	81
26	Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines. <i>RMD Open</i> , 2016, 2, e000282.	3.8	77
27	Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 393-399.	0.9	77
28	Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1808-1817.	0.9	74
29	Glucocorticoid Dosages and Acute Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. <i>Arthritis and Rheumatology</i> , 2019, 71, 1329-1338.	5.6	74
30	Concise guidance: diagnosis and management of giant cell arteritis. <i>Clinical Medicine</i> , 2010, 10, 381-386.	1.9	68
31	Investigational Analysis Reveals a Potential Role for Neutrophils in Giant-Cell Arteritis Disease Progression. <i>Circulation Research</i> , 2014, 114, 242-248.	4.5	68
32	Patient-reported Outcomes in Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2012, 39, 795-803.	2.0	64
33	Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 657-664.	3.4	62
34	Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. <i>Journal of Rheumatology</i> , 2008, 35, 270-7.	2.0	61
35	Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. <i>RMD Open</i> , 2019, 5, e001020.	3.8	56
36	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020, 59, 487-494.	1.9	56

#	ARTICLE	IF	CITATIONS
37	Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcome. <i>Family Practice</i> , 2008, 25, 328-333.	1.9	55
38	Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e328-e336.	3.9	52
39	Assessing Vasculitis in Giant Cell Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability Exercises. <i>Journal of Rheumatology</i> , 2018, 45, 1289-1295.	2.0	49
40	Efficacy and safety of mavrimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 653-661.	0.9	49
41	Delays in recognition and management of giant cell arteritis: results from a retrospective audit. <i>Clinical Rheumatology</i> , 2011, 30, 259-262.	2.2	47
42	Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review. <i>RMD Open</i> , 2015, 1, e000100.	3.8	47
43	A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren's Syndrome. <i>PLoS ONE</i> , 2015, 10, e0143970.	2.5	45
44	Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation. <i>Arthritis Research and Therapy</i> , 2015, 17, 195.	3.5	40
45	Treatment and outcomes of large vessel arteritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 325-337.	3.3	39
46	Imaging in Giant Cell Arteritis. <i>Current Rheumatology Reports</i> , 2015, 17, 52.	4.7	39
47	Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 75-90.	1.9	38
48	Polymyalgia rheumatica: The mess we are now in and what we need to do about it. <i>Arthritis and Rheumatism</i> , 2006, 55, 518-520.	6.7	37
49	Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis. <i>RMD Open</i> , 2016, 2, e000137.	3.8	36
50	Prevention of glucocorticoid morbidity in giant cell arteritis. <i>Rheumatology</i> , 2018, 57, ii11-ii21.	1.9	34
51	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1160-1166.	0.9	34
52	Improvement in diagnosis and management of musculoskeletal conditions with one-stop clinic-based ultrasonography. <i>Modern Rheumatology</i> , 2009, 19, 53-56.	1.8	31
53	Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors. <i>Rheumatology</i> , 2011, 50, 2014-2022.	1.9	31
54	A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis. <i>Rheumatology and Therapy</i> , 2020, 7, 793-810.	2.3	30

#	ARTICLE	IF	CITATIONS
55	Probability-based algorithm using ultrasound and additional tests for suspected GCA in a fast-track clinic. <i>RMD Open</i> , 2020, 6, e001297.	3.8	29
56	Diagnosis and management of giant cell arteritis. <i>British Journal of General Practice</i> , 2012, 62, 329-330.	1.4	28
57	Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis. <i>Rheumatology</i> , 2020, 59, 3717-3726.	1.9	26
58	Neuro-ophthalmic complications in giant cell arteritis. <i>Current Allergy and Asthma Reports</i> , 2008, 8, 323-330.	5.3	25
59	Current understanding and management of giant cell arteritis and polymyalgia rheumatica. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 913-928.	3.0	24
60	Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study. <i>Journal of Rheumatology</i> , 2016, 43, 1085-1092.	2.0	24
61	Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool. <i>RMD Open</i> , 2020, 6, e001417.	3.8	24
62	New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. <i>Rheumatology</i> , 2022, 61, 2915-2922.	1.9	24
63	Reliability Exercise for the Polymyalgia Rheumatica Classification Criteria Study: The Oranjewoud Ultrasound Substudy. <i>International Journal of Rheumatology</i> , 2009, 2009, 1-5.	1.6	23
64	Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1477-1486.	0.9	23
65	Giant cell arteritis: a review. <i>Eye and Brain</i> , 2013, 5, 23.	2.5	21
66	The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, 2299-2307.	1.9	21
67	Characterising those with incident polymyalgia rheumatica in primary care: results from the PMR Cohort Study. <i>Arthritis Research and Therapy</i> , 2016, 18, 200.	3.5	20
68	Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. <i>Rheumatology</i> , 2016, 55, 1466-1476.	1.9	20
69	Improvement in diagnosis and management of musculoskeletal conditions with one-stop clinic-based ultrasonography. <i>Modern Rheumatology</i> , 2009, 19, 53-56.	1.8	20
70	Polymyalgia rheumatica and giant cell arteritis: management of two diseases of the elderly. <i>Ageing Health</i> , 2011, 7, 633-645.	0.3	19
71	Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study. <i>RMD Open</i> , 2017, 3, e000426.	3.8	19
72	The epidemiology of polymyalgia rheumatica in primary care: a research protocol. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 102.	1.9	18

#	ARTICLE	IF	CITATIONS
73	Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy. <i>Arthritis Care and Research</i> , 2017, 69, 1714-1723.	3.4	18
74	Current and emerging therapies in large-vessel vasculitis. <i>Rheumatology</i> , 2018, 57, 1513-1524.	1.9	18
75	Improved renal function in diabetic patients with acute gout treated with anakinra. <i>Kidney International</i> , 2015, 88, 195-196.	5.2	17
76	Giant cell arteritis: new concepts, treatments and the unmet need that remains. <i>Rheumatology</i> , 2019, 58, 1123-1125.	1.9	17
77	Physical activity but not sedentary activity is reduced in primary Sjögren's syndrome. <i>Rheumatology International</i> , 2017, 37, 623-631.	3.0	16
78	“Slope sign”: a feature of large vessel vasculitis?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1738-1738.	0.9	16
79	Concise guidance: diagnosis and management of polymyalgia rheumatica. <i>Clinical Medicine</i> , 2010, 10, 270-274.	1.9	15
80	Role of the halo sign in the assessment of giant cell arteritis: a systematic review and meta-analysis. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab059.	0.7	15
81	Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss. <i>Rheumatology</i> , 2021, 60, 4361-4366.	1.9	15
82	Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage. <i>Lancet Rheumatology</i> , The, 2021, 3, e886-e895.	3.9	15
83	Patient and Physician Expectations of Add-On Treatment With Golimumab for Rheumatoid Arthritis: Relationships Between Expectations and Clinical and Quality of Life Outcomes. <i>Arthritis Care and Research</i> , 2014, 66, 1799-1807.	3.4	13
84	A 26-week feasibility study comparing the efficacy and safety of modified-release prednisone with immediate-release prednisolone in newly diagnosed cases of giant cell arteritis. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 285-291.	1.9	13
85	Halo score (temporal artery, its branches and axillary artery) as a diagnostic, prognostic and disease monitoring tool for Giant Cell Arteritis (GCA). <i>BMC Rheumatology</i> , 2020, 4, 35.	1.6	13
86	Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update. <i>Polish Archives of Internal Medicine</i> , 2020, 131, 171-181.	0.4	13
87	A probability score to aid the diagnosis of suspected giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 104-108.	0.8	12
88	Clinical observations on the significance of raised cardiac troponin-T in patients with myositis of varying etiologies seen in rheumatology practice. <i>Clinical Rheumatology</i> , 2010, 29, 1107-1111.	2.2	11
89	Giant cell arteritis. <i>BMJ: British Medical Journal</i> , 2011, 342, d3019-d3019.	2.3	11
90	Diagnosis and management of polymyalgia rheumatica. <i>British Journal of General Practice</i> , 2012, 62, 275-276.	1.4	10

#	ARTICLE	IF	CITATIONS
91	Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. <i>Rheumatology</i> , 2015, 55, kev373.	1.9	9
92	Profile of tocilizumab and its potential in the treatment of giant cell arteritis. <i>Eye and Brain</i> , 2018, Volume 10, 1-11.	2.5	9
93	Long-Term Efficacy and Safety of Leflunomide in Large-Vessel Giant Cell Arteritis. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e297-e300.	0.9	9
94	Polymyalgia rheumatica and giant cell arteritis. <i>British Journal of Hospital Medicine (London)</i> , 2018, 10, 622-628.	0.5	8
95	Comment on: British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: reply. <i>Rheumatology</i> , 2020, 59, e163-e164.	1.9	8
96	Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry. <i>Swiss Medical Weekly</i> , 2018, 148, w14588.	1.6	7
97	Giant Cell Arteritis: Beyond Corticosteroids. <i>Drugs and Aging</i> , 2015, 32, 591-599.	2.7	6
98	Polymyalgia rheumatica: strategies for efficient practice and quality assurance. <i>Rheumatology International</i> , 2015, 35, 1781-1789.	3.0	6
99	Circulating interleukin-6 as a biomarker in a randomized controlled trial of modified-release prednisone vs immediate-release prednisolone, in newly diagnosed patients with giant cell arteritis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1900-1904.	1.9	6
100	Identification of an activated neutrophil phenotype in polymyalgia rheumatica during steroid treatment: a potential involvement of immune cell cross-talk. <i>Clinical Science</i> , 2019, 133, 839-851.	4.3	6
101	Balancing on the edge: implications of a UK national audit of the use of BSR-BHPR guidelines for the diagnosis and management of polymyalgia rheumatica. <i>RMD Open</i> , 2015, 1, e000095.	3.8	5
102	The role of vascular ultrasound in managing giant cell arteritis in ophthalmology. <i>Survey of Ophthalmology</i> , 2020, 65, 218-226.	4.0	5
103	Imaging indications in polymyalgia rheumatica. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 39-48.	0.3	4
104	Polymyalgia rheumatica in older adults. <i>Aging Health</i> , 2013, 9, 483-495.	0.3	4
105	Response to: "Halo Score: missing large vessel giant cell arteritis" do we need a modified Halo Score? by Chattopadhyay and Ghosh. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e119-e119.	0.9	4
106	Current and innovative therapeutic strategies for the treatment of giant cell arteritis. <i>Expert Opinion on Orphan Drugs</i> , 2021, 9, 161-173.	0.8	4
107	Musculoskeletal ultrasonography: to keep pace with progress or be left behind?. <i>International Journal of Rheumatic Diseases</i> , 2008, 11, 109-117.	1.9	3
108	Contribution of imaging in Polymyalgia Rheumatica. <i>Joint Bone Spine</i> , 2013, 80, 228-229.	1.6	3

#	ARTICLE	IF	CITATIONS
109	12. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gevokizumab in the treatment of giant cell arteritis. <i>Rheumatology</i> , 2014, 53, i7-i7.	1.9	3
110	Response to: "Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: a retrospective study from routine care" by Molina Collada et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e176-e176.	0.9	3
111	Response to: "Correspondence on "Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia" by Evangelatos et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e43-e43.	0.9	3
112	Diagnosis and assessment of polymyalgia rheumatica: a step forward. <i>Aging Health</i> , 2012, 8, 395-397.	0.3	2
113	Apport de l'imagerie dans la pseudo-polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition) Tj ETQq1 1 0.784314 rgBT /Over</i>	0.0	2
114	THU0286...MANAGEMENT OF TAKAYASU ARTERITIS: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS. , 2019, , .		2
115	Response to: "Diagnostic accuracy of novel ultrasonographic halo score for giant cell arteritis: methodological issues" by Ghajari and Sabour. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e106-e106.	0.9	2
116	A case report of neurosarcoidosis successfully treated with an infliximab biosimilar after a relapse while on dual therapy. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 356-357.	0.8	2
117	Treatment of polymyalgia rheumatica. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 211-220.	0.8	1
118	P7. Gender differences in health-related quality of life in polymyalgia rheumatica. <i>Rheumatology</i> , 2014, 53, i14-i14.	1.9	1
119	2015 EULAR "ACR recommendations for polymyalgia rheumatica: the message and next steps. <i>Rheumatology</i> , 2016, 55, 955-956.	1.9	1
120	54. Binocular sight loss: uncommon, yet a devastating complication of GCA. <i>Rheumatology Advances in Practice</i> , 2019, 3, .	0.7	1
121	Response to: "Correspondence to "Slope sign": a feature of large vessel vasculitis" by Milchert et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 80, annrhumdis-2019-216690.	0.9	1
122	Excellent Response to Leflunomide in a Case of Large-Vessel Giant Cell Arteritis Demonstrated Simultaneously by Clinical, Laboratory, Ultrasound, and Positron Emission Tomography/Computed Tomography Parameters. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e254-e255.	0.9	1
123	Comment on: Diagnosing giant cell arteritis: a comprehensive practical guide for the practicing rheumatologist. <i>Rheumatology</i> , 2022, , .	1.9	1
124	Metabolic and Crystal Arthropathies [70-72]: 70. Single Intramuscular Depot Methylprednisolone Injection: A Convenient, Efficacious and Safe Treatment for Gouty Arthritis in an Inpatient Setting. <i>Rheumatology</i> , 2010, 49, i59-i61.	1.9	0
125	133. National Audit on Diagnosis and Management of Polymyalgia Rheumatica. <i>Rheumatology</i> , 2014, 53, i110-i110.	1.9	0
126	A pragmatic approach to imaging in large vessel vasculitis. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 767-775.	0.8	0



#	ARTICLE	IF	CITATIONS
127	009â€fUltrasound Compared with Biopsy in the Diagnosis of Suspected Giant Cell Arteritis. Rheumatology, 2016, 55, i37-i37.	1.9	0
128	038â€fHow Common are Giant Cell Arteritis Symptoms in Patients with Polymyalgia Rheumatica? Results from an Incident Primary Care Cohort. Rheumatology, 0, , .	1.9	0
129	Emerging therapies in large vessel vasculitis. International Journal of Rheumatic Diseases, 2016, 19, 741-746.	1.9	0
130	91.â€fA journey between the ologists: is it lupus?. Rheumatology Advances in Practice, 2018, 2, .	0.7	0
131	1160â€fUpdate on the role of ultrasound in GCA/LVV and current training options in the UK. Rheumatology, 2019, 58, .	1.9	0
132	Polymyalgia rheumatica and large vessel vasculitis: a case report. Rheumatology Advances in Practice, 2020, 4, rkaa049.	0.7	0
133	Comment on: Diagnostic accuracy of ultrasound for detecting large-vessel giant cell arteritis using FDG PET/CT as the reference. Rheumatology, 2021, 60, e66-e66.	1.9	0